This process could potentially facilitate the integration of newly emerged sRNAs into bacterial regulatory networks.

This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.

It is proposed that the lack of requirement for specificity in these interactions might facilitate the integration of new metabolic pathways.

Answering these questions will facilitate the integration of geriatric issues into future mechanistic and clinical studies that affect management and care of acute kidney injury.